埃罗妥珠单抗联合来那度胺和地塞米松治疗不适合移植的新诊断多发性骨髓瘤患者(ELOQUENT-1):一项开放标签、多中心、随机、3期试验
ELOQUENT-1是一项开放标签、多中心、随机3期试验,在19个国家185个中心纳入748例不适合造血干细胞移植的新诊断多发性骨髓瘤患者,1:1随机接受埃罗妥珠单抗联合来那度胺和地塞米松或来那度胺和地塞米松。中位随访70.6个月,两组中位无进展生存期无显著差异(31.4个月 vs 29.5个月,HR 0.93,95.71%CI 0.77-1.12;分层log-rank p=0.44)。
要点
- 不适合移植的新诊断骨髓瘤中,埃罗妥珠单抗联合方案未显著改善无进展生存期(HR 0.93,p=0.44)。
- 两组中位无进展生存期分别为31.4个月与29.5个月,最短随访65.3个月。
- 最常见的3-4级治疗相关不良事件为中性粒细胞减少(17% vs 21%)。
核心结论
- 在不适合造血干细胞移植的新诊断多发性骨髓瘤患者中,埃罗妥珠单抗联合来那度胺和地塞米松与来那度胺和地塞米松相比未显著改善无进展生存期。
- 作者认为这些数据有助于丰富治疗格局,但需要进一步研究以寻找改善一线治疗的方法。
研究设计与样本
- ELOQUENT-1为开放标签、多中心、随机3期试验,在19个国家的185家医院、肿瘤诊所和研究中心开展。
- 纳入年龄≥18岁、新诊断未经治疗、有症状、不适合大剂量化疗联合造血干细胞移植且ECOG体能状态≤2分的多发性骨髓瘤患者。
- 748例患者按1:1随机分配至埃罗妥珠单抗联合来那度胺和地塞米松组或来那度胺和地塞米松组(每组374例),按ISS分期(I-II期 vs III期)、年龄(<75岁 vs ≥75岁)和ECOG体能状态(0 vs 1-2)分层。
- 主要终点为意向治疗人群按欧洲血液和骨髓移植学会标准主要定义评估的无进展生存期。
主要发现
- 2011年8月4日至2014年6月19日共随机分配748例患者(每组374例),742例接受治疗;埃罗妥珠单抗联合组371例中333例(90%)停止治疗,来那度胺和地塞米松组371例中339例(91%)停止治疗。
- 患者中位年龄73.0岁(IQR 69.0-78.0),294例(39%)年龄≥75岁;大多数为白人(711例[95%])和男性(412例[55%])。
- 最短随访65.3个月时,中位无进展生存期在埃罗妥珠单抗联合组为31.4个月(95%CI 26.2-36.8),来那度胺和地塞米松组为29.5个月(95%CI 23.5-34.3),两组无显著差异(HR 0.93,95.71%CI 0.77-1.12;分层log-rank p=0.44)。
- 中位随访70.6个月(IQR 35.1-79.2)。
- 最常见的3-4级治疗相关不良事件为中性粒细胞减少,埃罗妥珠单抗联合组64例(17%)/371 vs 来那度胺和地塞米松组79例(21%)/371;研究药物毒性作为报告死因在两组分别为5例(1%)vs 4例(1%)。
临床怎么用
- 原文结论为埃罗妥珠单抗联合来那度胺和地塞米松与来那度胺和地塞米松相比未显著改善不适合造血干细胞移植的新诊断多发性骨髓瘤患者的无进展生存期,作者指出需要进一步研究以改善一线治疗,原文未据此给出推荐。
局限性
- 作者在解释中指出需要进一步研究以寻找改善一线治疗的方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Elotuzumab plus lenalidomide and dexamethasone has shown improved progression-free and overall survival versus lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. We aimed to assess these regimens in patients with newly diagnosed multiple myeloma who are ineligible for haematopoietic stem-cell transplantation (HSCT). METHODS: ELOQUENT-1 is an open-label, multicentre, randomised, phase 3 trial conducted at 185 hospitals, oncology practices, and research centres in 19 countries. Eligible patients were aged 18 years or older with newly diagnosed, untreated, symptomatic myeloma and not candidates for high-dose therapy plus HSCT, and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower. Patients were randomly assigned (1:1) to receive elotuzumab plus lenalidomide and dexamethasone or lenalidomide and dexamethasone using an interactive voice response system, stratified by the International Staging System (ISS; stage I-II vs III), age (<75 years vs ≥75 years), and ECOG performance status (0 vs 1-2). Patients in the elotuzumab plus lenalidomide and dexamethasone group received elotuzumab administered intravenously at 10 mg/kg on days 1, 8, 15, and 22 during cycles 1 and 2, days 1 and 15 during cycles 3-18, and then at 20 mg/kg on day 1 for subsequent cycles. In both treatment groups, patients received 25 mg lenalidomide orally on days 1-21 of each cycle and 40 mg dexamethasone on days 1, 8, 15, and 22 of each cycle. The primary endpoint was progression-free survival, as per the primary definition from European Society for Blood and Marrow Transplantation criteria in all randomly assigned patients (intention-to-treat population). This study is registered with ClinicalTrials.gov, NCT01335399 (completed). FINDINGS: Between Aug 4, 2011, and June 19, 2014, 748 patients were randomly assigned (374 in each treatment group) and 742 patients received treatment (333 (90%) of 371 in the elotuzumab plus lenalidomide and dexamethasone group vs 339 (91%) of 371 in the lenalidomide and dexamethasone group discontinued treatment). The median age of patients was 73·0 years (IQR 69·0-78·0), 294 (39%) patients were 75 years or older. Most patients were White (711 [95%]) and male (412 [55%]). At a minimum follow-up of 65·3 months, the median progression-free survival was not significantly different between the groups: 31·4 months (95% CI 26·2-36·8) in the elotuzumab plus lenalidomide and dexamethasone group versus 29·5 months (23·5-34·3) in the lenalidomide and dexamethasone group (HR 0·93, 95·71% CI 0·77-1·12; stratified log-rank p=0·44). The median follow-up was 70·6 months (IQR 35·1-79·2). The most common grade 3-4 treatment-related adverse event was neutropenia (64 [17%] of 371 vs 79 [21%] of 371). Study drug toxicity was the reported cause of death in five (1%) versus four (1%) patients. INTERPRETATION: Elotuzumab plus lenalidomide and dexamethasone did not significantly improve progression-free survival versus lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for HSCT. Although these data contribute to the treatment landscape, further research is needed to find ways to improve treatments in the front-line setting. FUNDING: Bristol Myers Squibb.
引用
- Dimopoulos MA, Richardson PG, Bahlis NJ, et al. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2022. PMID: 35550060. doi:10.1016/S2352-3026(22)00103-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。